Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Forecast calculation
1.4 Data collection
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 360º synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of infectious disease
3.2.1.2 Rising number of pharmaceutical and biotechnology companies
3.2.1.3 Growing collaborations for antibiotics development
3.2.1.4 Increasing focus on generic medications
3.2.2 Industry pitfalls & challenges
3.2.2.1 Antibiotic resistance
3.2.2.2 Regulatory complexities
3.3 Growth potential analysis
3.4 Pipeline assessment
3.5 Regulatory landscape
3.6 Porter’s analysis
3.6.1 Supplier power
3.6.2 Buyer power
3.6.3 Threat of new entrants
3.6.4 Threat of substitutes
3.6.5 Industry rivalry
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2018-2032 ($ Million)
5.1 Key trends
5.2 Penicillins
5.3 Cephalosporins
5.4 Macrolides
5.5 Quinolones
5.6 Aminoglycosides
5.7 Tetracyclines
5.8 Other drug classes
Chapter 6 Market Estimates and Forecast, By Type, 2018 – 2032 ($ Million)
6.1 Key trends
6.2 Branded
6.3 Generics
Chapter 7 Market Estimates and Forecast, By Spectrum, 2018 – 2032 ($ Million)
7.1 Key trends
7.2 Broad-spectrum antibiotics
7.3 Narrow-spectrum antibiotics
Chapter 8 Market Estimates and Forecast, By Drug Origin, 2018 – 2032 ($ Million)
8.1 Key trends
8.2 Natural
8.3 Semisynthetic
8.4 Synthetic
Chapter 9 Market Estimates and Forecast, By Route of Administration, 2018 – 2032 ($ Million)
9.1 Key trends
9.2 Oral
9.3 Parenteral
9.4 Other routes of administration
Chapter 10 Market Estimates and Forecast, By Application, 2018 – 2032 ($ Million)
10.1 Key trends
10.2 Respiratory infections
10.3 Urinary tract infections (UTIs)
10.4 Skin and soft tissue infections
10.5 Sexually transmitted infections (STIs)
10.6 Gastrointestinal infections
10.7 Other applications
Chapter 11 Market Estimates and Forecast, By Distribution Channel, 2018 – 2032 ($ Million)
11.1 Key trends
11.2 Hospital pharmacies
11.3 Retail pharmacies
11.4 Online pharmacies
Chapter 12 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Million)
12.1 Key trends, by region
12.2 North America
12.2.1 U.S.
12.2.2 Canada
12.3 Europe
12.3.1 Germany
12.3.2 UK
12.3.3 France
12.3.4 Spain
12.3.5 Italy
12.3.6 Rest of Europe
12.4 Asia Pacific
12.4.1 Japan
12.4.2 China
12.4.3 India
12.4.4 Australia
12.4.5 South Korea
12.4.6 Rest of Asia Pacific
12.5 Latin America
12.5.1 Brazil
12.5.2 Mexico
12.5.3 Rest of Latin America
12.6 Middle East & Africa
12.6.1 South Africa
12.6.2 Saudi Arabia
12.6.3 Rest of Middle East & Africa
Chapter 13 Company Profiles
13.1 Abbott Laboratories
13.2 AbbVie, Inc.
13.3 Allergan plc
13.4 Basilea Pharmaceutica Ltd.
13.5 Bayer AG
13.6 Bristol Myers Squibb
13.7 Cipla Inc.
13.8 Daiichi Sankyo Company Ltd.
13.9 Eli Lilly & Co.
13.10 GlaxoSmithKline plc.
13.11 Johnson & Johnson
13.12 Lupin Inc.
13.13 Melinta Therapeutics LLC
13.14 Merck & Co.
13.15 Novartis AG
13.16 Pfizer Inc.
13.17 Sandoz
13.18 Sanofi
13.19 Teva Pharmaceutical Industries Ltd.
13.20 Viatris Inc.
